SRF board approves new chloromethane plant to meet Indian pharma demand

By Gareth Macdonald

- Last updated on GMT

SRF plans two new plants
SRF plans two new plants

Related tags International trade Chemical industry

SRF Limited has unveiled plans for a second chloromethane plant just two months after India imposed anti-dumping tariffs on Chinese and Russian imports. 

The firm announced its plans for the facility – and a second multipurpose chemical plant – as part of a INR3.45bn ($52m) construction project unveiled this week.

The facilities will be at SRF’s production site in Dahej, Gujarat. One will make a variety of chemicals for the pharmaceutical and agrochemicals sector.

The other, which will cost INR1.8bn to construct, will produce chloromethane, which is used in the manufacture of chemicals like methylene dichloride and chloroform.

Pharma sector

Methylene dichloride is the chemical that makes sipping birds sip.

Dichloromethane is the fluid found in the sipping bird toy (source Wikipedia)

It is also used in the production of refrigerants – which are SRF’s core business - and in the manufacture of active pharmaceutical ingredients (API).

In a filing​ on the Bombay Stock Exchange (BSE) on August 8, SRF said the rational for doubling methylene dichloride capacity was meeting “the growing needs of its customers in the pharma sector.”

The plant will be operational in December 2017 and will have capacity to make 40,000 tonnes of chloromethane a year.

At present, SRF’s facility in Bhiwadi, Rajasthan produces around 40,000 tonnes of the chemical a year.

Anti-dumping measures

News of SRF’s investment comes just a few months​ after the Indian Government confirmed it will introduce tariffs on methylene dichloride supplied by manufacturers in China and Russia.

According to a statement by the Ministry of Finance on May 31​ it decided to impose a tariff on Chinese and Russian imports after determining that “the subject goods have been exported to India from the subject countries below normal values.”

It added that this activity – a practice known as dumping in which manufacturers sell products at less than cost – had hurt domestic producers. The tariff has been imposed for a minimum of five years, backdated to December 8.

The two new plants are the first pharma-focused investments SRF has made since it acquired DuPont’s Dymal inhaler propellant business in January​ 2015. 

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more